Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
GE

NASDAQ · GERN

Geron Corporation

Healthcare · Biotechnology

$0.89

Down-$0.05 (-5.47%)

Updated Nov 1, 2026, 12:25 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
884.12M
P/E ratio
-11.55
Dividend yield
0.00%
52-week range
$0.84 – $2.01
Volume
18.81M
Avg. volume
7.6M

Price performance · GERN

GERN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

GERN closed at $0.89 after 20 trading sessions, down 26.08% for the selected period.

Last close
$0.89
Period change
-26.08%
Period low
$0.89
Period high
$1.24
Daily close
View OHLC price history
GERN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.93$0.9381$0.8606$0.894418.81M
Oct 29, 2026$0.954$1.01$0.9068$0.946232.35M
Oct 28, 2026$1.04$1.05$0.84$0.968581.72M
Oct 27, 2026$1.16$1.19$1.14$1.156.71M
Oct 26, 2026$1.12$1.17$1.10$1.1511.09M
Oct 23, 2026$1.145$1.15$1.08$1.1211.23M
Oct 22, 2026$1.16$1.19$1.12$1.137.18M
Oct 21, 2026$1.24$1.24$1.14$1.168.92M
Oct 20, 2026$1.20$1.24$1.18$1.243.56M
Oct 19, 2026$1.199$1.21$1.175$1.204.91M
Oct 16, 2026$1.24$1.24$1.17$1.173.96M
Oct 15, 2026$1.20$1.24$1.20$1.235.68M
Oct 14, 2026$1.20$1.205$1.17$1.195.43M
Oct 13, 2026$1.22$1.225$1.18$1.207.59M
Oct 12, 2026$1.22$1.24$1.205$1.223.98M
Oct 9, 2026$1.22$1.26$1.21$1.2255.64M
Oct 8, 2026$1.205$1.22$1.17$1.2210.16M
Oct 7, 2026$1.21$1.215$1.185$1.205.14M
Oct 6, 2026$1.20$1.24$1.19$1.215.72M
Oct 5, 2026$1.20$1.23$1.18$1.216.37M

Latest GERN news

The latest Smart Investors Daily articles mentioning GERN.

Stock researchCompany · Overview

GERN research

Overview

Company profile and research snapshot.

Company profile

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.89
Implied upside
—
Analysts
—
GERN recent ratings
DateFirmRatingTarget
Oct 29, 2026WedbushOutperform—
Oct 28, 2026NeedhamBuy—
Nov 5, 2025NeedhamBuy—
Jul 10, 2025Goldman SachsSell—
May 8, 2025ScotiabankSector Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company’s website. Geron will host a conference call and webc

Yahoo · Oct 19, 2026

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective October 16, 2026, it granted stock options to purchase an aggregate of 570,000 shares of common stock to three newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.1

Yahoo · Oct 12, 2026

Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced two oral presentations and one poster presentation highlighting imetelstat in patients with lower-risk myelodysplastic syndrome

Benzinga · Oct 8, 2026

Geron Q2 2026 Earnings Call: Complete Transcript

Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By